As with many transformative efforts, we believe developing collaborations and partnerships is a key part of our strategy to successfully leverage our RTGel platform to enhance our product portfolio in uro-oncology and beyond.
We currently have an exclusive worldwide license agreement with Allergan to evaluate BotuGel™, proprietary RTGel-based formulation of BOTOX®* (onabotulinumtoxin A) in development for the treatment of overactive bladder (OAB), currently in a Phase 2 clinical trial.
Are you interested in partnering with UroGen?
Please contact us at firstname.lastname@example.org.
*BOTOX is a registered trademark of Allergan Pharmaceuticals